Not all impactful innovation involves the development of new chemical or biological entities, and the value of such innovation must be recognized in pricing processes argues Gebro Pharma Switzerland CEO Marcel Plattner.
We understand you serve as the head of the executive committee for market access and pricing within the Swiss pharmaceutical association (VIPS).
VIPS is the association of pharmaceutical companies operating in Switzerland and as such the association is focused on the Swiss pharmaceutical market. As the main goal we want to ensure that the hurdles to market access and pricing levels are well balanced with the necessary investments companies have to provide for innovations.
"As a country of eight million inhabitants with its own regulatory agency, many specific rules, the need for significant local knowledge, and a very high cost of labor that overall the cost of doing business is very high for a pharmaceutical company in Switzerland – and thus prices must be somewhat higher to compensate for that."
